CLINUVEL to Cut Workforce and Relocate to New York Amid Broader Biopharma Restructuring

CLINUVEL PHARMACEUTICALS has announced plans to reduce its global workforce by up to 20% and relocate its headquarters to New York to prioritize the U.S. market. This strategic shift coincides with significant headcount reductions across the sector, including major cuts at Novartis and potential staff departures at EMD Serono due to new office attendance policies. These developments highlight a broader industry trend of realigning operational expenditures and geographic footprints to better access capital and key commercial territories.

CLINUVEL PHARMACEUTICALS is implementing a strategic reorganization that includes cutting between 10% and 20% of its global workforce, potentially affecting up to 21 of its 104 employees. As part of this transition, the company will move its corporate headquarters from Australia to New York at the beginning of 2027. This relocation is specifically designed to enhance regulatory engagement and commercial partnerships within the United States, where CLINUVEL’s late-stage programs for vitiligo target an estimated patient population of 6 million. The company stated that this restructuring is a prerequisite to align spending with current revenue and to unlock deeper, more liquid U.S. capital pools.

EMD Serono, the U.S. healthcare division of Merck KGaA, is facing potential staff reductions of up to 70 employees at its Research & Development Institute in Billerica, Massachusetts. The potential cuts are tied to a new policy requiring R&D staff to work in the office at least three days per week starting in September, with those unable or unwilling to comply being offered severance. This move comes as parent company Merck KGaA reported that its healthcare business—which encompasses both drug development and medical devices—experienced a 3.4% year-on-year revenue decline, earning €2.1 billion ($2.4 billion) in the first quarter despite overall group growth.

The broader industry continues to see large-scale workforce adjustments, with Novartis announcing its largest round of layoffs this year by cutting 322 positions in East Hanover, New Jersey. This brings the total number of affected employees at that location to 572, part of a wider plan that has seen at least 792 total roles eliminated by the company in 2026, including the scheduled closure of a production site in Wehr, Germany. Similarly, Genentech is laying off 103 people at its South San Francisco headquarters, affecting its research and early development group as well as other business units. These reductions across major players reflect a sector-wide focus on streamlining operations and concentrating resources on high-impact projects critical to advancing clinical portfolios.